Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04194541
Other study ID # 20191046
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 28, 2020
Est. completion date March 8, 2021

Study information

Verified date March 2023
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this research is to determine how the types of wound dressings affect quality of life for people with Hidradenitis Suppurativa (HS).


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date March 8, 2021
Est. primary completion date March 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women =18 years of age - Diagnosed with Hidradenitis Suppurativa (all stages of disease) by Dermatologist - Presence of at least one lesion with active drainage - Willing and able to provide informed consent Exclusion Criteria: - Subjects younger than 18-years-old. - Prisoners - Pregnant or lactating women - Adults unable to consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cutimed Sorbact Hydroactive B wound dressing
Wound dressing applied and changed as needed.
Cutimed Siltect wound dressing
Wound dressing applied and changed as needed.
Sorbion Sana multi-star wound dressing
Wound dressing applied and changed as needed.

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dermatology Life Quality Index (DLQI) Scores Participant quality of life as measured via DLQI. DLQI has a total score ranging from 0-30 with the higher score indicating more impairment on the participant's quality of life. At Baseline, at 6 Weeks
Secondary Average Pain as Assessed by the Numerical Rating Scale (NRS) The average pain reported over the last 24 hours will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. At Baseline, at 6 Weeks
Secondary Maximal Pain as Assessed by the Numerical Rating Scale (NRS) The pain rating at its worse over the last 24 hours will be reported as the maximal pain using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. At Baseline, at 6 Weeks
Secondary Sleep Rating Sleep rating will be evaluated using a 5 point Likert scale ranging from 1-5 with the higher score indicating increased sleep disturbance. At Baseline, at 6 Weeks
Secondary Drainage Rating Lesion drainage rating will be evaluated using a 4 point Likert scale ranging from 1-4 with the higher score indicating increased lesion draining. For participants with multiple wounds/lesions, the drainage rating will be a comprehensive assessment of all wounds/lesions. At Baseline, at 6 Weeks
Secondary Odor Rating Lesion odor rating will be evaluated using a 4 point Likert scale ranging from 1-4 with the higher score indicating increased lesion odor. For participants with multiple wounds/lesions, the odor rating will be a comprehensive assessment of all wounds/lesions. At Baseline, at 6 Weeks
Secondary Number of Participants at Each Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Grading HS-PGA Scale scores patient disease severity as one of the following: clear, minimal, mild, moderate, severe, and very severe. The number of participants scored at each scale will be reported. At 6 Weeks
Secondary Average Frequency of Dressing Changes Participant reported frequency of dressing changes per wound per day. For participants with multiple wounds/lesions, the frequency of dressing changes will be a comprehensive assessment of all wounds/lesions. 6 Weeks
Secondary Number of Participants Reporting Overall Dressing Preference for Specific Body Part Overall dressing preference will be reported as the number of participants preferring to use a particular wound dressing in the kit provided. At Baseline
Secondary Number of Participants Reporting Dressing Preference for Each Specific Body Part Participant reported dressing preference for specific body parts for each of the interventions received. Visit 1 (Day 14)
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2